Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, Rani Therapeutics Holdings Inc’s stock clocked out at $1.56, up 0.65% from its previous closing price of $1.55. In other words, the price has increased by $0.65 from its previous closing price. On the day, 1.63 million shares were traded. RANI stock price reached its highest trading level at $1.575 during the session, while it also had its lowest trading level at $1.49.
Ratios:
To gain a deeper understanding of RANI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.26 and its Current Ratio is at 0.26.
Upgrades & Downgrades
In the most recent recommendation for this company, Oppenheimer on August 02, 2024, initiated with a Outperform rating and assigned the stock a target price of $17.
On June 14, 2024, Maxim Group started tracking the stock assigning a Buy rating and target price of $15.
On June 13, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $10.Rodman & Renshaw initiated its Buy rating on June 13, 2024, with a $10 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 23 ’25 when IMRAN MIR A bought 2,083,334 shares for $0.60 per share. The transaction valued at 1,260,417 led to the insider holds 2,083,334 shares of the business.
South Cone Investments Limited sold 4,000,000 shares of RANI for $11,074,000 on Oct 21 ’25. The 10% Owner now owns 2,379,194 shares after completing the transaction at $2.77 per share. On Oct 20 ’25, another insider, South Cone Investments Limited, who serves as the 10% Owner of the company, sold 1,923,000 shares for $2.41 each. As a result, the insider received 4,637,314 and left with 6,379,194 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RANI now has a Market Capitalization of 191327024 and an Enterprise Value of 161461312. For the stock, the TTM Price-to-Sale (P/S) ratio is 157.98. Its current Enterprise Value per Revenue stands at 134.551 whereas that against EBITDA is -4.033.
Stock Price History:
The Beta on a monthly basis for RANI is 0.43, which has changed by -0.10919541 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, RANI has reached a high of $3.87, while it has fallen to a 52-week low of $0.39. The 50-Day Moving Average of the stock is 1.99%, while the 200-Day Moving Average is calculated to be 59.28%.
Shares Statistics:
It appears that RANI traded 17.88M shares on average per day over the past three months and 2466960 shares per day over the past ten days. A total of 97.55M shares are outstanding, with a floating share count of 89.73M. Insiders hold about 8.02% of the company’s shares, while institutions hold 13.55% stake in the company. Shares short for RANI as of 1764288000 were 10601934 with a Short Ratio of 0.59, compared to 1761868800 on 4968738. Therefore, it implies a Short% of Shares Outstanding of 10601934 and a Short% of Float of 11.21.
Earnings Estimates
The stock of Rani Therapeutics Holdings Inc (RANI) is currently drawing attention from 3.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.14 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.35 and -$0.58 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is -$0.32, with 3.0 analysts recommending between -$0.18 and -$0.59.
Revenue Estimates
A total of 4 analysts have provided revenue estimates for RANI’s current fiscal year. The highest revenue estimate was $10.17M, while the lowest revenue estimate was $200k, resulting in an average revenue estimate of $5.19M. In the same quarter a year ago, actual revenue was $1.03M
